Ketone bodies, specific intermediate products of fatty acid β-oxidation in the liver, are not metabolic wastes but critical alternative energy sources when glucose supply is insufficient. Synthesized in hepatic mitochondria and utilized by extrahepatic tissues, they consist of three components with distinct clinical roles: β-hydroxybutyrate (accounting for 70% of total ketones, the main pathogenic substance of ketoacidosis and core marker for ketone testing), acetoacetate (20%, the primary target of urinary ketone assays but highly unstable), and acetone (10%, volatile and exhaled, causing the characteristic fruity breath in ketoacidosis patients). Under physiological conditions, glucose is the body’s main energy source, suppressing fat oxidation and keeping ketone levels extremely low. When glucose utilization is impaired, insulin is deficient, or starvation stress occurs, fat breaks down excessively, leading to rapid ketone accumulation and triggering ketosis or even life-threatening ketoacidosis.
Elevated ketone levels stem from two core etiological categories, both rooted in insufficient glucose metabolism forcing lipolysis for energy. Diabetic ketosis, the high-risk pathological subtype, arises from absolute or relative insulin deficiency coupled with elevated glucagon. Common triggers include type 1 diabetes, interrupted insulin therapy, type 2 diabetes complicated by infection, stress, surgery or trauma, hyperglycemic hyperosmolar state with impaired glucose utilization, and non-adherence to hypoglycemic medications. Insulin is the only endogenous hormone that inhibits ketogenesis, and severe insulin deficiency leads to uncontrolled hepatic lipolysis and massive ketone synthesis, rapidly progressing to diabetic ketosis (DK) or diabetic ketoacidosis (DKA). Non-diabetic ketosis, often benign or stress-induced and frequently misdiagnosed in outpatient settings, is caused by energy deprivation, including prolonged fasting, extreme dieting, severe vomiting, hyperemesis gravidarum, high fever, excessive alcohol consumption on an empty stomach, and SGLT2 inhibitor use which may induce euglycemic ketoacidosis, a highly insidious clinical condition.
Accurate ketone measurement is the cornerstone of clinical decision-making, and blood ketone testing is universally recognized as the gold standard for diagnosis and efficacy monitoring, while urinary ketone testing only serves as an initial screening tool. Standard reference ranges define normal blood ketone levels as <0.3 mmol/L, mild elevation (suspected ketosis) as 0.3–0.9 mmol/L, confirmed ketosis as ≥1.0 mmol/L, and DKA (critical value) as ≥3.0 mmol/L. Urinary ketone assays have significant limitations: they only detect acetoacetate, fail to identify the most abundant and harmful β-hydroxybutyrate, and reflect ketone excretion from several hours prior, presenting a marked lag time. During treatment recovery, β-hydroxybutyrate is metabolized first while acetoacetate persists, creating a misleading phenomenon of falling blood ketones but rising urinary ketones that may lead to incorrect assessment of treatment failure. For all patients with suspected ketosis, blood ketone monitor must be prioritized to avoid misdiagnosis, especially for those taking SGLT2 inhibitors, as urinary ketone results are often unreliable in this population.
The core principle of ketone management is to terminate excessive lipolysis by replenishing glucose, correcting dehydration, and restoring effective insulin action, with stratified treatment based on etiology and severity. For benign non-diabetic ketosis (blood ketones <1.0 mmol/L, normal blood glucose, no acidosis), oral or intravenous glucose supplementation and fluid replacement to restore circulating perfusion are the primary interventions, with most cases resolving rapidly within 2–4 hours without insulin. For diabetic ketosis and DKA, rapid normal saline infusion for volume expansion, low-dose intravenous insulin infusion to suppress ketogenesis, and electrolyte correction form the core treatment. During the entire treatment process, regular blood ketone analyzer should be performed every 1–2 hours in the acute phase to evaluate treatment response, adjust insulin dosage, and confirm resolution of ketosis once levels drop below 0.3 mmol/L.
In conclusion, ketone bodies are not exclusive to diabetes but represent a universal warning signal of glucose and lipid metabolism imbalance, energy stress, and insulin dysfunction. Clinical practice should prioritize standardized blood ketone testing, distinguish between diabetic and non-diabetic etiologies, and base interventions on dynamic trends rather than single measurements. Mastering ketone metabolism, testing protocols, and stratified management strategies is an essential clinical competency for endocrinologists, emergency physicians, and general practitioners, enabling timely diagnosis and effective intervention to reduce the mortality of ketoacidosis.
Post time: Nov-16-2026
